维立西呱与美托洛尔联合治疗射血分数降低型心力衰竭的临床研究 点击下载
| 论文标题： | 维立西呱与美托洛尔联合治疗射血分数降低型心力衰竭的临床研究 |
| 英文标题： | |
| 中文摘要： | 目的 研究维立西呱与美托洛尔联合治疗射血分数降低型心力衰竭（HFrEF）的有效性与安全性。方法前瞻性纳入2022年1月至2025年1月于邯郸市第一医院收治的136例HFrEF患者，采用随机数字表法分为对照组与试验组，各68例。在抗心力衰竭基础治疗的同时，对照组加用美托洛尔，试验组加用美托洛尔和维立西呱，均连续治疗6个月。对比两组临床疗效和治疗前后的心功能指标、血清学相关指标、生活质量及不良反应发生情况。结果试验组脱落3例，对照组脱落4例。试验组临床总有效率为95.38%，显著高于对照组的75.00%（P＜0.05）。与治疗前相比，治疗后两组患者的左心室收缩末内径、左心室舒张末内径、同型半胱氨酸水平、N末端B型利钠肽原水平、C反应蛋白水平、明尼苏达心力衰竭生活质量调查表评分均显著下降（P＜0.05），左心室射血分数均显著上升（P＜0.05），且试验组改善效果较对照组更为明显（P＜0.05）。两组患者不良反应发生率比较差异无统计学意义（P＞0.05）。结论相较于单用美托洛尔，维立西呱联合美托洛尔可进一步改善HFrEF患者心功能，更好地调控血清学相关指标、提升生活质量与整体临床疗效，且安全性良好。 |
| 英文摘要： | OBJECTIVE To study the efficacy and safety of the combination therapy of vericiguat and metoprolol in the treatment of heart failure with reduced ejection fraction （HFrEF）. METHODS Prospective inclusion of 136 HFrEF patients admitted to the Handan First Hospital from January 2022 to January 2025， divided into a control group and an experimental group using a random number table method， 68 cases per group. At the same time as anti heart failure foundation， the control group was treated with metoprolol， while the experimental group was treated with metoprolol and vericiguat for 6 months. Compare the clinical efficacy and cardiac function indicators， serological related indicators， quality of life before and after treatment， and incidence of adverse reactions between the two groups. RESULTS Three cases were lost in the experimental group and four cases were lost in the control group. The total clinical effective rate of the experimental group was 95.38%， significantly higher than the control group’s 75.00% （P＜0.05）. Compared to before treatment， after treatment， the left ventricular end-systolic diameter， left ventricular end-diastolic diameter， homocysteine level， N-terminal pro-B-type natriuretic peptide level， C-reactive protein level， and Minnesota Living with Heart Failure Questionnaire scores of both groups of patients significantly decreased （P＜0.05）， while the left ventricular ejection fraction significantly increased （P＜0.05）， and the improvement effect of the experimental group was more significant than that of the control group （P＜0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients （P＞0.05）. CONCLUSIONS Compared to metoprolol alone， the combination of vericiguat and metoprolol can further improve heart function in HFrEF patients， better regulate serological related indicators， enhance quality of life and overall clinical efficacy， and has good safety. |
| 期刊： | 2026年第37卷第15期 |
| 作者： | 刘丹丹；何卓群；寇丹 |
| 英文作者： | LIU Dandan，HE Zhuoqun，KOU Dan |
| 关键字： | 射血分数降低型心力衰竭；美托洛尔；维立西呱；有效性；安全性 |
| KEYWORDS： | heart failure with reduced ejection fraction； |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！